AI assistant
CSL Ltd. — M&A Activity 2015
Aug 2, 2015
17854_rns_2015-08-02_564ec2dc-5023-484d-96bd-fcc7ac0ee26b.pdf
M&A Activity
Open in viewerOpens in your device viewer
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
For immediate release
3 August 2015
CSL completes Novartis influenza vaccine business acquisition
CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that it has now closed its transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.
As foreshadowed in CSL’s release to the Australian Securities Exchange on 31 July, closing of the transaction will allow CSL to integrate the influenza vaccines division with its subsidiary, bioCSL. The combined business will create the second largest influenza vaccine business in the US$4 billion global industry and will have manufacturing plants in the US, UK, Germany and Australia, a commercial presence in approximately 20 countries, a differentiated product portfolio and strong pandemic and pre-pandemic franchises.
For further information, please contact:
Investors: Mark Dehring Head of Investor Relations CSL Limited Phone: +613 9389 3407 Email: [email protected]
Media: Sharon McHale Head of Public Affairs CSL Limited Mobile +61 409 978 314 Email: [email protected]
US Media:
Natalie de Vane Snr. Director Corporate Communications CSL Behring Phone: +1 610 878 4468 Email: [email protected]
==> picture [99 x 7] intentionally omitted <==